ERBB2 and breast cancer: The results of the phase 3 PHERDA study indicated that HPy significantly improved the pCR rate compared to H monotherapy combined with chemotherapy (41.0% vs 22%, P < 0.0001) (6), thereby establishing the role of Py in NAT for HER2-positive BC.